SUNHAWK BIO (7759) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of SUNHAWK BIO stock TWD 36.29, price TWD 50.50, that is 28.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
SUNHAWK BIO
7759 · TWOExpensive (fair value 28% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
20‑month range 26.90 TWD – 182.00 TWD · fair‑value band 27.22 TWD – 45.36 TWD · the 50.50 TWD price screens above the 36.29 TWD fair value. As of Nov 16, 2026.
Every Wednesday you see whether SUNHAWK BIO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sunhawk Vision Biotech, Inc. operates as a drug development company that develops microRNA therapeutic eye drops. Its flagship product is SHJ002 eye drops. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.
Stock analysis
SUNHAWK BIO (7759) currently trades at 50.50 TWD, while our estimate is 36.29 TWD, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 27.22 TWD (bear) to 45.36 TWD (bull), the price of 50.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
SUNHAWK BIO reported revenue of 0 TWD in FY2023 versus 952K TWD in FY2021. Reported net income was −172M TWD in FY2025.
Key figures
Market cap 3.5B TWD (≈ $107M) Micro · EPS (TTM) −1.89 TWD · Return on equity −27.3% · Return on assets (EBIT) −30.1% (5-year average) · Free cash flow −145M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, 7759 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare SUNHAWK BIO with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 7759 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 7759 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 7759 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 7759 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 7759 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 7759 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 7759 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 7759 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 7759 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 7759 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is SUNHAWK BIO (7759) overvalued or undervalued?
What is the fair value of 7759?
What is the quality score of 7759?
What is the price target for SUNHAWK BIO (7759)?
What is the SUNHAWK BIO stock forecast for 2026?
What is the intrinsic value of SUNHAWK BIO (7759)?
Is SUNHAWK BIO stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 7759?
How much is SUNHAWK BIO worth?
What do the bullish and bearish scenarios say about 7759?
How solid is the balance sheet of SUNHAWK BIO (7759)?
How far is 7759 from its 52-week high?
Which stocks are comparable to SUNHAWK BIO?
Is SUNHAWK BIO stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of SUNHAWK BIO (7759)?
What should I pay attention to with SUNHAWK BIO right now?
Key figures of SUNHAWK BIO
How large is the market capitalisation of SUNHAWK BIO (7759)?
What are the earnings per share of SUNHAWK BIO (7759)?
What is the return on equity of SUNHAWK BIO (7759)?
What is the EBIT return on assets of SUNHAWK BIO (7759)?
How much free cash flow does SUNHAWK BIO (7759) generate?
Watch SUNHAWK BIO in the live analysis
One click puts SUNHAWK BIO on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.